Marinus Pharmaceuticals, Inc. (MRNS)
MRNSPrice: $0.55
Fair Value: 🔒
🔒score
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinas... more
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercializatio... more
Description
Shares
| Market Cap | $30.37M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Scott N. Braunstein |
| IPO Date | 2014-07-31 | CAGR | 0.68% |
| Employees | 165 | Website | marinuspharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.25% | Total Yield | 0.25% |
MRNS chart loading...
Fundamentals
Technicals
| Enterprise Value | $114.53M | P/E Ratio | -0.22 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 1.83 | P/B Ratio | -0.47 |
| P/CF Ratio | -0.63 | P/FCF Ratio | -0.59 |
| EPS | $-2.47 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 1.63% | Gross Margin | 0.9% |
| Operating Margin | -3.21% | Profit Margin | -3.62% |
| ROE | 1.05% | ROA | -0.94% |
| ROCE | -1.83% | Current Ratio | 1.66 |
| Quick Ratio | 1.47 | Cash Ratio | 1.22 |
| Debt/Equity | -0.84 | Interest Coverage | -6.3 |
| Altman Z Score | -20.13 | Piotroski Score | 3 |